Results 191 to 200 of about 46,559 (243)

Dual pharmacological targeting of coactivator‐associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ketone bodies are liver‐derived circulating energy metabolites that positively impact most hallmarks of ageing. Ketone bodies increase during calorie restriction and fasting, two of the more widely perceived methods to increase health span.
Tábata Bergonci, Troels Kjær Rosenbæk, Samuel J. Windross, Ulrik B. Keiding, Estéfano Pinilla, Katrine P. Stuckert, Jakob Hansen, Camilla B. Nielsen, Jemila Peter Gomes, Lucy R. Davies, Johan Palmfeldt, Volker Loeschcke, Charlotte U. Andersen, Ulf Simonsen, Thomas B. Poulsen, Mogens Johannsen   +15 more
wiley   +1 more source

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

British Journal of Pharmacology, EarlyView.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, Robert Fredriksson, Francisco Lagunas‐Rangel, Alexander S. Hauser, Stefan Knapp, Jörgen Jonsson, Helgi B. Schiöth   +8 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer, Paraskevi Sotiropoulou, Koussai Bouker, Dennis Svedberg, Rebekkah Hammar, Hester Bange, Per Larsson, André Mateus, Daniel R. Dietrich, Per Artursson   +9 more
wiley   +1 more source

AKR1C3 Binds β‐Trcp to Promote the Degradation of TFRC to Protect Hepatocellular Carcinoma From Ferroptosis

Cancer Science, EarlyView.
In this study, we show that aldo‐keto reductase family 1 member C3 (AKR1C3), a protein highly expressed in ferroptosis resistant hepatocellular carcinoma cells, acts as an enzyme‐independent scaffold protein by promoting the nuclear export of β‐transducin repeat protein (β‐TrCP) and its binding to transferrin receptor (TFRC) in an enzyme‐independent ...
Lei Qi, Jingyi Hua, Di Pan, Wanwan Yang, Geng Tian, Fangyu Ye, Lingxiang Liu, Yuhan Mao, Qinglong Guo, Haopeng Sun, Li Zhao   +10 more
wiley   +1 more source

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, EarlyView.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis. [PDF]

Eur J Clin Pharmacol
Santana DS, Porto BC, Cardoso RB, Lopes GMM, Gimenez LGS, Passerotti CC, Maia R, Almeida FG, da Silva Sardenberg RA, da Cruz JAS.   +9 more
europepmc   +1 more source

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients. [PDF]

Investig Clin Urol
Chung Y, Jeong SJ, Song SH, Hong SK.
europepmc   +1 more source

Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate. [PDF]

Low Urin Tract Symptoms
Filzmayer M, Traumann MI, Humke C, Müller MJ, Mandel PC, Kluth LA, Becker A, Chun FK, Kosiba M.   +8 more
europepmc   +1 more source